Progesterone is the most frequently underdosed, most commonly skipped, and most poorly understood hormone in the BHRT toolkit. Providers who are new to hormone optimization often treat progesterone as an afterthought - something added primarily to protect the uterine lining in women on estrogen. Providers who understand progesterone's full clinical profile treat it as a therapeutic agent in its own right - one with profound effects on sleep, mood, anxiety, and neurologic function that go far beyond its role as estrogen's counterpart.
This article covers progesterone's mechanisms of action, the clinical consequences of deficiency and underdosing, the critical differences between delivery methods, and a practical prescribing framework for incorporating progesterone appropriately into hormone optimization protocols.
PROGESTERONE IS A NEUROSTEROID
The most important thing to understand about progesterone that most providers were not taught in training is that it is a neurosteroid. Progesterone and its metabolites - particularly allopregnanolone - cross the blood-brain barrier and act directly on the central nervous system.
The primary CNS mechanism involves GABA-A receptors. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors - the same receptors targeted by benzodiazepines, barbiturates, and alcohol. When progesterone levels are adequate, its metabolites enhance GABAergic tone in the brain, producing the calming, anxiolytic, and sleep-promoting effects that patients on appropriate progesterone therapy frequently describe.
When progesterone levels are deficient - as they commonly are in perimenopausal and postmenopausal women - GABAergic tone is reduced. The clinical consequence is exactly what you would predict from reduced GABA activity - insomnia, anxiety, irritability, and a heightened stress response. These are among the most common and most distressing symptoms of perimenopause, and they are frequently attributed to estrogen fluctuation or psychological stress when the underlying driver is progesterone deficiency.
This neurosteroid mechanism is why oral micronized progesterone taken at bedtime is one of the most consistently effective interventions for perimenopausal insomnia - and why patients often report dramatic sleep improvement within the first week of starting it. The GABAergic effect is rapid, dose-dependent, and clinically meaningful in a way that no synthetic progestin reproduces.
UTERINE PROTECTION: THE NON-NEGOTIABLE INDICATION
While the neurosteroid effects of progesterone are often underappreciated, its role in uterine protection is well established and non-negotiable for any provider prescribing estrogen to a woman with an intact uterus.
Estrogen stimulates endometrial proliferation. Without progesterone opposition, this proliferation continues unchecked - leading to endometrial hyperplasia and, over time, an increased risk of endometrial cancer. The relationship between unopposed estrogen and endometrial cancer risk is one of the most well-established findings in gynecologic oncology, with studies demonstrating a significantly elevated risk in women on estrogen alone compared to those on combined estrogen-progesterone therapy.
Every provider prescribing estrogen therapy to a woman with a uterus must include progesterone. This is not a recommendation - it is a standard of care requirement. Providers who prescribe estrogen without progesterone to women with intact uteri are exposing their patients to a documented and preventable risk and themselves to a significant liability.
The one clinical scenario that sometimes generates confusion is the use of local vaginal estrogen at very low doses for genitourinary syndrome of menopause. At doses used for local vaginal effect, systemic absorption is minimal and the evidence does not support routine addition of progesterone solely for uterine protection. However, this exception applies to low-dose local therapy only - any systemic estrogen therapy in a woman with a uterus requires progesterone.
WHY PROVIDERS UNDERDOSE PROGESTERONE
Several patterns of progesterone underdosing are common in hormone optimization practice, each with its own clinical consequences.
Treating progesterone as optional for women without a uterus. Women who have had a hysterectomy do not require progesterone for uterine protection - that indication is absent. However, the neurosteroid benefits of progesterone are independent of uterine status. A woman without a uterus who is experiencing insomnia, anxiety, and mood instability may benefit significantly from progesterone therapy. The absence of a uterus does not eliminate the neurologic indication for progesterone ā€” it simply removes the uterine protection indication. Many providers fail to make this distinction and withhold progesterone from hysterectomized women who would benefit from it.
Using doses that are adequate for uterine protection but inadequate for neurologic effect. The dose of progesterone required to protect the endometrium - typically 100 mg daily - may be insufficient to produce meaningful neurosteroid effects in patients with significant sleep and mood symptoms. Many patients require 200 mg or higher at bedtime to experience the sleep and anxiolytic benefits of progesterone therapy. Providers who dose to the minimum required for uterine protection without considering the neurologic indication frequently produce a clinical result that feels incomplete to the patient.
Using topical progesterone when oral is indicated for neurologic effect. Topical progesterone creams produce minimal serum progesterone levels and do not generate the allopregnanolone metabolite in quantities sufficient to produce meaningful GABAergic effects. For patients whose primary progesterone indication is sleep and mood - rather than uterine protection - oral micronized progesterone is the evidence-supported delivery method. Topical progesterone may have a role in symptom management for some patients but should not be used as a substitute for oral therapy when neurologic effects are the therapeutic goal.
ORAL VS. TOPICAL VS. VAGINAL DELIVERY
The choice of progesterone delivery method significantly affects clinical outcomes and should be made intentionally rather than by default.
Oral micronized progesterone. This is the bioidentical progesterone form with the strongest evidence base for both uterine protection and neurologic effects. Available as Prometrium in FDA-approved form and as compounded oral micronized progesterone from various pharmacies. Oral delivery produces significant first-pass hepatic metabolism, generating allopregnanolone and other neuroactive metabolites that are responsible for the GABAergic effects. Serum progesterone levels after oral administration are variable and do not accurately reflect tissue levels - this is why symptom assessment rather than serum levels is the more reliable guide to dosing adequacy with oral micronized progesterone.
Topical progesterone creams. Transdermal progesterone cream produces variable and generally low serum progesterone levels. The evidence for topical progesterone providing adequate endometrial protection at typical cream doses is weak - topical progesterone should not be relied upon as the sole progesterone source in women on systemic estrogen with an intact uterus unless serum and endometrial monitoring confirms adequacy. Topical progesterone does not generate the neuroactive metabolites responsible for the sleep and anxiolytic benefits of oral therapy in meaningful quantities.
Vaginal progesterone. Vaginal progesterone suppositories or gels produce high local uterine concentrations through first uterine pass effect and are primarily used in fertility medicine for luteal phase support. Their role in hormone optimization practice is limited but may be appropriate in specific clinical scenarios.
Progesterone in pellets. Some pellet therapy protocols include progesterone pellets, though the evidence base for pellet progesterone is considerably thinner than for testosterone and estradiol pellets. Progesterone is chemically challenging to compress into a stable pellet form, and the clinical outcomes data for pellet progesterone is less robust than for oral or topical delivery.
A PRACTICAL PRESCRIBING FRAMEWORK
The following framework provides a starting point for incorporating progesterone into hormone optimization protocols. Individual patient response should guide ongoing dose adjustments.
For postmenopausal women on systemic estrogen with an intact uterus. Oral micronized progesterone 100 to 200 mg nightly is the standard starting approach. Begin at 100 mg and increase to 200 mg if sleep, mood, or anxiety symptoms remain inadequately addressed. Document the uterine protection indication and monitor with endometrial assessment per standard gynecologic guidelines.
For perimenopausal women with progesterone deficiency symptoms. Oral micronized progesterone 100 to 200 mg nightly in the luteal phase - days 14 through 28 - is the appropriate starting approach for women who are still cycling. Continuous dosing may be more appropriate for women with very irregular cycles or those approaching menopause.
For women without a uterus with sleep or mood symptoms. Oral micronized progesterone 100 to 200 mg nightly is appropriate when neurologic symptoms are present. Document the neurologic indication clearly in the chart - this is an off-label use in women without a uterine protection need and requires appropriate informed consent and documentation.
For women on testosterone pellets. Consider whether the addition of oral micronized progesterone at bedtime would address any residual sleep or mood symptoms not fully resolved by testosterone optimization alone. Progesterone and testosterone are complementary in their neurologic effects and many patients benefit from both.
BOTTOM LINE
Progesterone is not a supporting player in hormone optimization - it is a primary therapeutic agent with profound neurologic effects that are independent of and in addition to its role in uterine protection. Providers who understand progesterone's full clinical profile, who dose it adequately for the neurologic indication, and who choose the delivery method that matches the therapeutic goal are providing a meaningfully higher level of care than those who treat it as an afterthought. The patients who benefit most are often those who have spent years being told their insomnia and anxiety are stress-related - when the answer was a nightly dose of progesterone all along.
